➀ The study introduces a biomimetic nanovaccine (AECM@PC7A) that combines IFN-γ-treated tumor cell membranes with a synthetic adjuvant (PC7A) to enhance neoantigen presentation and activate the STING pathway, addressing limitations of conventional cancer vaccines;

➁ In preclinical models, the vaccine triggered robust T-cell responses, reduced tumor growth and metastasis, and demonstrated synergy with immune checkpoint inhibitors, leading to prolonged survival and immune memory;

➂ The platform offers a scalable approach for personalized immunotherapy by leveraging tumor-specific neoantigens and simplified manufacturing processes, showing promise for clinical translation.

➀ Researchers at the University of Michigan developed nanodiscs to target cholesterol levels in GBM tumors, showing promise in increasing survival rates in treated mice;

➁ Current treatment limitations for GBM include surgery, radiation, and chemotherapy, with no cure available;

➂ The nanodiscs deliver LXR agonists to increase cellular pumps for cholesterol removal, leading to cancer cell destruction, and stimulate the immune system to target tumors.

➀ Researchers from the University of Queensland are developing novel nanoparticles to enhance the effectiveness of immunotherapies for treating triple-negative breast cancer (TNBC);

➁ TNBC is an aggressive form of breast cancer with high mortality rates;

➂ The nanoparticles are designed to boost the immune response of TNBC patients to treatments, potentially leading to improved efficacy of immunotherapy.